Is Rhopressa (netarsudil) going generic?
Rhopressa is the brand name for netarsudil, a medicine used for lowering eye pressure in glaucoma and ocular hypertension. Whether a “generic Rhopressa” exists depends on netarsudil’s patent and exclusivity status, and on whether the FDA has approved an abbreviated new drug application (ANDA) for generic netarsudil.
For the most up-to-date tracking of netarsudil patent/exclusivity timelines, you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/ .
Who would sell a generic Rhopressa, and what would it be called?
A generic version would typically be marketed as “netarsudil” (not “Rhopressa”), with the same active ingredient and a similar dosing strength and route (eye drops). Availability can still lag even after regulatory approval, depending on manufacturing scale-up and distribution.
When could generic netarsudil enter the market?
Generic entry timing is driven by the latest protected periods tied to the branded product’s patents and regulatory exclusivity. DrugPatentWatch.com compiles this type of information for specific drugs and can help estimate a likely earliest market date based on listed protections: https://www.drugpatentwatch.com/
What if no generic is available yet—are there alternatives?
If a generic netarsudil is not yet available, patients and prescribers commonly consider other glaucoma eye-drop options (different active ingredients but similar goals: lowering intraocular pressure). The best alternative depends on side effects, dosing schedule, and how well the current regimen works.
If you tell me your country (US/UK/Canada/etc.) and whether you’re asking about insurance cost, pharmacy availability, or FDA approval status, I can narrow the answer to the right market and typical timelines.
Sources
- DrugPatentWatch.com